Cargando…

Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy

Response to immunotherapy widely varies among cancer patients and identification of parameters associating with favourable outcome is of great interest. Here we show longitudinal monitoring of peripheral blood samples of non-small cell lung cancer (NSCLC) patients undergoing anti-PD1 therapy by high...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leung, Elaine Lai-Han, Li, Run-Ze, Fan, Xing-Xing, Wang, Lily Yan, Wang, Yan, Jiang, Zebo, Huang, Jumin, Pan, Hu-Dan, Fan, Yue, Xu, Hongmei, Wang, Feng, Rui, Haopeng, Wong, Piu, Sumatoh, Hermi, Fehlings, Michael, Nardin, Alessandra, Gavine, Paul, Zhou, Longen, Cao, Yabing, Liu, Liang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444872/ https://www.ncbi.nlm.nih.gov/pubmed/37607911 http://dx.doi.org/10.1038/s41467-023-40631-0

Ejemplares similares

Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non–Small Cell Lung Cancer
por: Li, Jia-Xin, et al.
Publicado: (2019)

Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment
por: Fehlings, Michael, et al.
Publicado: (2019)

Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy
por: Huang, Jumin, et al.
Publicado: (2022)

SCD1 is associated with tumor promotion, late stage and poor survival in lung adenocarcinoma
por: Huang, Jun, et al.
Publicado: (2016)

The key role of sphingolipid metabolism in cancer: New therapeutic targets, diagnostic and prognostic values, and anti-tumor immunotherapy resistance
por: Li, Run-Ze, et al.
Publicado: (2022)

Immunotherapy for Pediatric Acute Lymphoblastic Leukemia: Recent Advances and Future Perspectives
por: Lv, Meng, et al.
Publicado: (2022)

LB-18. Broad and Prevalent SARS-CoV-2 CD8+ T Cell Response in Recovered COVID-19 Individuals Demonstrates Kinetics of Early Differentiation
por: Kared, Hassen, et al.
Publicado: (2020)

Identification of a Novel Protein Arginine Methyltransferase 5 Inhibitor in Non-small Cell Lung Cancer by Structure-Based Virtual Screening
por: Wang, Qianqian, et al.
Publicado: (2018)

Herbal formula BaWeiBaiDuSan alleviates polymicrobial sepsis-induced liver injury via increasing the gut microbiota Lactobacillus johnsonii and regulating macrophage anti-inflammatory activity in mice
por: Fan, Xiaoqing, et al.
Publicado: (2023)

Author correction to ‘Herbal formula BaWeiBaiDuSan alleviates polymicrobial sepsis-induced liver injury via increasing the gut microbiota Lactobacillus johnsonii and regulating macrophage anti-inflammatory activity in mice’ [Acta Pharmaceutica Sinica B 13 (2023) 1164–1179]
por: Fan, Xiaoqing, et al.
Publicado: (2023)

PA-MSHA induces inflamed tumor microenvironment and sensitizes tumor to anti-PD-1 therapy
por: Huang, Min, et al.
Publicado: (2022)

Immune checkpoints and immunotherapy in non-small cell lung cancer: Novel study progression, challenges and solutions
por: Ma, Lin-Rui, et al.
Publicado: (2021)

Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy
por: Ding, Peng, et al.
Publicado: (2022)

Evodiamine suppresses non-small cell lung cancer by elevating CD8(+) T cells and downregulating the MUC1-C/PD-L1 axis
por: Jiang, Ze-Bo, et al.
Publicado: (2020)

Remarkable response to anti-PD1 immunotherapy in refractory metastatic high-grade myxofibrosarcoma patient: A case report
por: Luo, Yi, et al.
Publicado: (2021)

CD8+ T cell responses in convalescent COVID-19 individuals target epitopes from the entire SARS-CoV-2 proteome and show kinetics of early differentiation
por: Kared, Hassen, et al.
Publicado: (2020)

Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut Microbiota
por: He, Daqiang, et al.
Publicado: (2021)

Proscillaridin A induces apoptosis and suppresses non-small-cell lung cancer tumor growth via calcium-induced DR4 upregulation
por: Li, Run-Ze, et al.
Publicado: (2018)

miR-20b promotes growth of non-small cell lung cancer through a positive feedback loop of the Wnt/β-catenin signaling pathway
por: Ren, Tao, et al.
Publicado: (2019)

Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells
por: Luo, Lian-Xiang, et al.
Publicado: (2017)

PD-1(+) mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy
por: Li, Jun, et al.
Publicado: (2022)

ROS-Responsive Berberine Polymeric Micelles Effectively Suppressed the Inflammation of Rheumatoid Arthritis by Targeting Mitochondria
por: Fan, Xing-xing, et al.
Publicado: (2020)

Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
por: Pei, Liping, et al.
Publicado: (2023)

The Updated Status and Future Direction of Immunotherapy Targeting B7-H1/PD-1 in Osteosarcoma
por: Fan, Meng-ke, et al.
Publicado: (2021)

PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer
por: Zhang, Yingzi, et al.
Publicado: (2022)

Detection of Single Cancer Cell Multidrug Resistance With Single Cell Bioanalyzer
por: Cai, Jun, et al.
Publicado: (2023)

Complement Mediated Signaling on Pulmonary CD103(+) Dendritic Cells Is Critical for Their Migratory Function in Response to Influenza Infection
por: Kandasamy, Matheswaran, et al.
Publicado: (2013)

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
por: Zhang, Min, et al.
Publicado: (2019)

Novel clinical biomarkers in blood and pleural effusion for diagnosing patients with tuberculosis distinguishing from malignant tumor
por: Wang, Jian, et al.
Publicado: (2022)

Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy
por: Gao, Yang, et al.
Publicado: (2020)

Clinical Study of Anti-PD-1 Immunotherapy Combined with Gemcitabine Chemotherapy in Multiline Treatment of Advanced Pancreatic Cancer
por: Liu, Yanfeng, et al.
Publicado: (2022)

Midkine inhibition enhances anti-PD-1 immunotherapy in sorafenib-treated hepatocellular carcinoma via preventing immunosuppressive MDSCs infiltration
por: Ding, Lijuan, et al.
Publicado: (2023)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

The role of exosomal PD-L1 in tumor immunotherapy
por: Wang, Jing, et al.
Publicado: (2021)

Bifidobacterium breve predicts the efficacy of anti‐PD‐1 immunotherapy combined with chemotherapy in Chinese NSCLC patients
por: Zhao, Honghui, et al.
Publicado: (2022)

Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents
por: Sun, Chengliang, et al.
Publicado: (2022)

Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy
por: Gao, Hannan, et al.
Publicado: (2020)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Celastrol Induces Apoptosis in Gefitinib-Resistant Non-Small Cell Lung Cancer Cells via Caspases-Dependent Pathways and Hsp90 Client Protein Degradation
por: Fan, Xing-Xing, et al.
Publicado: (2014)

Clinical applications of PD-L1 bioassays for cancer immunotherapy
por: Liu, Delong, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_e7l7c33okci8083t3072fph9pm